当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Double stenting of oesophagus and airways in palliative treatment of patients with oesophageal cancer is efficient but associated with a high morbidity.

Double stenting of oesophagus and airways in palliative treatment of patients with oesophageal cancer is efficient but associated with a high morbidity.

Abstract：

BACKGROUND:Double stenting of oesophagus and airways may be required in palliative treatment of patients with locally advanced oesophageal cancer. AIM:To assess feasibility, efficacy and complications occurring in patients with locally advanced oesophageal cancer receiving both oesophagus and airways stenting. METHODS:In one single centre between 1997 and 2005, among 180 patients with locally advanced oesophageal cancer treated by the palliative placement of a self-expanding metal stent, patients requiring double stenting of oesophagus and airways were identified. Clinical efficacy, complications and survival were retrospectively collected. RESULTS:Fifteen patients (8.3% of 180) required a double stenting at follow-up. Symptomatic efficacy of oesophagus and airways stenting was 86.7% for dysphagia and 100% for dyspnoea. Median survival after the second stent insertion was 99 days. Life-threatening early complications occurred in three patients after double stenting (20%), including two deaths following oesophageal perforation and massive haemoptysis, respectively. Procedure-related mortality was 13.3%. CONCLUSIONS:Double stenting of oesophagus and airways is feasible in patients with locally advanced oesophageal cancer, with a relevant clinical efficacy. However, early major complications including procedure-related death may occur in as many as 20% of patients. This treatment should be reserved to very selected patients with severe symptoms and end-stage disease.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Lecleire S,Antonietti M,Di Fiore F,Ben-Soussan E,Bota S,Hellot MF,Thiberville L,Michel P,Lerebours E,Ducrotté P

doi

10.1111/j.1365-2036.2007.03280.x

subject

Has Abstract

pub_date

2007-04-15 00:00:00

pages

955-63

issue

8

eissn

0269-2813

issn

1365-2036

pii

APT3280

journal_volume

25

pub_type

杂志文章

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Review article: irritable bowel syndrome.

    abstract：:Irritable bowel syndrome is a disease that can be diagnosed positively on the basis of an established series of criteria and limited exclusion of organic disease. It is the most common disease diagnosed by gastroenterologists and affects about 20% of all people at any one time. Symptoms fluctuate, and the overall prev...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.1997.84256000.x

    authors： Camilleri M,Choi MG

    更新日期：1997-02-01 00:00:00

  • Usefulness of a delayed test for the diagnosis of Helicobacter pylori infection in bleeding peptic ulcer.

    abstract：AIM:To evaluate (i) the diagnostic usefulness of a delayed test in initially negative patients; and (ii) the reliability of the rapid urease test, histology or a combination of the two to diagnose Helicobacter pylori during emergency endoscopy in a large clinical practice series. PATIENTS AND METHODS:Records of patien...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.02726.x

    authors： Güell M,Artigau E,Esteve V,Sánchez-Delgado J,Junquera F,Calvet X

    更新日期：2006-01-01 00:00:00

  • Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.

    abstract：BACKGROUND:Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL). AIM:A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2008.03884.x

    authors： Quigley EM,Vandeplassche L,Kerstens R,Ausma J

    更新日期：2009-02-01 00:00:00

  • Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, doub

    abstract：BACKGROUND:Alginates form a raft above the gastric contents, which may suppress gastro-oesophageal reflux; however, inconsistent effects have been reported in mechanistic and clinical studies. AIMS:To visualise reflux suppression by an alginate-antacid [Gaviscon Advance (GA), Reckitt Benckiser, UK] compared with a non...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.12318

    authors： Sweis R,Kaufman E,Anggiansah A,Wong T,Dettmar P,Fried M,Schwizer W,Avvari RK,Pal A,Fox M

    更新日期：2013-06-01 00:00:00

  • Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer.

    abstract：AIM:To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients. METHODS:Forty H. pylori-positive patients with duodenal ulcer were randomized to receive 20 mg omeprazole o.m. or b.d. for 1 month plus 500 mg clarithromy...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1999.00653.x

    authors： Dani R,Queiroz DM,Dias MG,Franco JM,Magalhães LC,Mendes GS,Moreira LS,De Castro LP,Toppa NH,Rocha GA,Cabral MM,Salles PG

    更新日期：1999-12-01 00:00:00

  • Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice.

    abstract：AIM:To compare lansoprazole 30 mg daily with ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. METHODS:In a double-blind, parallel group, randomized, mutlicentre study conducted in 32 general practices in the UK, 213 patients were randomized to receive lansoprazole 30 mg daily, and...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1997.00179.x

    authors： Jones RH,Baxter G

    更新日期：1997-06-01 00:00:00

  • The effect of bolus viscosity on swallowing function in neurogenic dysphagia.

    abstract：AIM:To assess the pathophysiology and treatment of neurogenic dysphagia. METHODS:46 patients with brain damage, 46 with neurodegenerative diseases and eight healthy volunteers were studied by videofluoroscopy while swallowing 3-20 mL liquid (20.4 mPa s), nectar (274.4 mPa s) and pudding (3931.2 mPa s) boluses. RESULT...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2006.03118.x

    authors： Clavé P,de Kraa M,Arreola V,Girvent M,Farré R,Palomera E,Serra-Prat M

    更新日期：2006-11-01 00:00:00

  • Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.

    abstract：BACKGROUND:HS-10234 is a novel prodrug of tenofovir developed to increase anti-viral potency and to reduce systemic toxicities. AIMS:To evaluate the tolerability, pharmacokinetics and anti-viral efficacy of HS-10234 in patients with chronic hepatitis B (CHB) infection METHODS: Treatment-naïve subjects with non-cirrhot...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16196

    authors： Zhang H,Hu Y,Wu M,Liu J,Zhu X,Li X,Chen H,Li C,Liu C,Niu J,Ding Y

    更新日期：2021-01-01 00:00:00

  • Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.

    abstract：BACKGROUND:The widespread use of eradication therapy for Helicobacter pylori in Japan has led to an increase in antibiotic-resistant strains and the problem of re-treatment in cases of eradication failure. AIM:To perform drug sensitivity testing for metronidazole in 92 H. pylori-positive patients who had failed eradic...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2003.01401.x

    authors： Murakami K,Sato R,Okimoto T,Nasu M,Fujioka T,Kodama M,Kagawa J

    更新日期：2003-01-01 00:00:00

  • Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures.

    abstract：BACKGROUND:In some cases, Helicobacter pylori infection persists even after three eradication treatments. AIM:To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. METHODS: DESIGN:Multicentre, prospective study. PATIENTS:In whom the following...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2012.05053.x

    authors： Gisbert JP,Castro-Fernandez M,Perez-Aisa A,Cosme A,Molina-Infante J,Rodrigo L,Modolell I,Cabriada JL,Gisbert JL,Lamas E,Marcos E,Calvet X

    更新日期：2012-04-01 00:00:00

  • End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.

    abstract：BACKGROUND:Methotrexate (MTX) is one of the most frequently prescribed drugs in contemporary medicine with a well-recognised hepatotoxic potential, for which stringent laboratory and histological surveillance has long been advocated. AIM:To estimate the population burden of end-stage methotrexate-related liver disease...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12912

    authors： Dawwas MF,Aithal GP

    更新日期：2014-10-01 00:00:00

  • Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre.

    abstract：BACKGROUND:Hepatitis vaccination is recommended in patients with chronic liver disease. AIM:To validate Current Procedural Terminology (CPT) codes and drug codes for hepatitis vaccination in administrative databases and determine vaccination rates in hepatitis C virus (HCV)-infected patients in a single large Veterans...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03827.x

    authors： Hachem CY,Kramer JR,Kanwal F,El-Serag HB

    更新日期：2008-11-01 00:00:00

  • Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis.

    abstract：BACKGROUND:Infliximab (IFX) therapy escalation during maintenance treatment occurs frequently in clinical practice in patients with ulcerative colitis (UC). Outcomes for these patients have not been described. AIM:To describe the prevalence of, and outcomes after, IFX escalation during maintenance therapy in patients ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2011.04986.x

    authors： Rostholder E,Ahmed A,Cheifetz AS,Moss AC

    更新日期：2012-03-01 00:00:00

  • Review article: the management of autoimmune hepatitis beyond consensus guidelines.

    abstract：BACKGROUND:Consensus guidelines aid in the diagnosis and management of autoimmune hepatitis, but they are frequently based on low-quality clinical evidence, conflicting experiences and divergent opinions. Recommendations may be weak, discrepant or non-existent at critical decision points. AIMS:To identify the decision...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.12381

    authors： Czaja AJ

    更新日期：2013-08-01 00:00:00

  • Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management.

    abstract：:A significant proportion of patients with gastro-oesophageal reflux disease (GERD) have Helicobacter pylori infection, but it is unclear whether or not H. pylori should be treated in this clinical setting. The aim of this review was to critically assess the relationship between H. pylori and GERD and its potential imp...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.1999.00460.x

    authors： O'Connor HJ

    更新日期：1999-02-01 00:00:00

  • Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis.

    abstract：BACKGROUND:Pregabalin has a broad spectrum of analgesic and antihyperalgesic activity in both basic and clinical studies. However, its mechanisms and sites of action have yet to be determined in humans. AIMS:To assess the antinociceptive effect of pregabalin on experimental gut pain in patients with visceral hyperalge...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2011.04802.x

    authors： Olesen SS,Graversen C,Olesen AE,Frøkjaer JB,Wilder-Smith O,van Goor H,Valeriani M,Drewes AM

    更新日期：2011-10-01 00:00:00

  • Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients.

    abstract：BACKGROUND:Liver cirrhosis is characterized by a silent phase until decompensation, which is defined by ascites, bleeding from esophageal varices or hepatic encephalopathy. AIM:To compare the clinical course, patterns of survival and causes of death by etiology during long-term follow-up in a large population-based co...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15255

    authors： Nilsson E,Anderson H,Sargenti K,Lindgren S,Prytz H

    更新日期：2019-06-01 00:00:00

  • Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study.

    abstract：BACKGROUND:It is unclear whether adherence to prescribing standards has been achieved in inflammatory bowel disease (IBD). AIM:To determine how prescribing of 5-aminosalicylates (5-ASAs), steroids and thiopurines has changed in response to emerging evidence. METHODS:We examined trends in oral and topical therapies in...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13700

    authors： Chhaya V,Saxena S,Cecil E,Subramanian V,Curcin V,Majeed A,Pollok RC

    更新日期：2016-09-01 00:00:00

  • Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.

    abstract：BACKGROUND:The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%-15% develops chronic antibiotic-dependent or refractory pouchitis which is usually hard to treat. AIM:To evaluate the effecti...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/apt.14479

    authors： Bär F,Kühbacher T,Dietrich NA,Krause T,Stallmach A,Teich N,Schreiber S,Walldorf J,Schmelz R,Büning C,Fellermann K,Büning J,Helwig U,German IBD Study Group.

    更新日期：2018-03-01 00:00:00

  • Review article: esomeprazole in the treatment of Helicobacter pylori.

    abstract：:Proton pump inhibitor-based triple therapy is the most commonly used treatment for eradication of Helicobacter pylori, with pooled eradication rates of approximately 90%. In the USA, per protocol eradication rates with 10-day proton pump inhibitor-based triple therapy are approximately 85%. Esomeprazole, a new proton ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.16.s4.13.x

    authors： Laine L

    更新日期：2002-07-01 00:00:00

  • Prevalence of coeliac disease in Northwest China: heterogeneity across Northern Silk road ethnic populations.

    abstract：BACKGROUND:Epidemiological data of coeliac disease are lacking from the central Asian region. AIMS:To verify the occurrence of coeliac disease amongst four major ethnic groups of Xinjiang Uyghur Autonomus Region, China. METHODS:2277 in-patients with gastrointestinal symptoms (1391 Han, 608 Uyghur, 146 Kazakh and 132 ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15737

    authors： Zhou C,Gao F,Gao J,Yuan J,Lu J,Sun Z,Xu M,Engel J,Hui W,Gilissen L,Chen H

    更新日期：2020-06-01 00:00:00

  • Lack of immunogenicity of hydrolysed wheat flour in patients with coeliac disease after a short-term oral challenge.

    abstract：BACKGROUND:A gluten-free diet is currently the only reliable therapeutic strategy that is approved for coeliac disease (CD). For many patients, however, compliance remains inadequate. AIM:To investigate the immunogenicity of wheat flour that was pre-treated with selected lactobacilli and fungal proteases (hydrolysed w...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.14175

    authors： Mandile R,Picascia S,Parrella C,Camarca A,Gobbetti M,Greco L,Troncone R,Gianfrani C,Auricchio R

    更新日期：2017-08-01 00:00:00

  • Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection.

    abstract：BACKGROUND:Functional dyspepsia is a problem that is difficult to treat in clinical practice. AIM:To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia. METHODS:Patients with functional dyspepsia (n=557) were divided a priori into two studies by Helicobacter pylori status, ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.2001.01074.x

    authors： Talley NJ,Riff DS,Schwartz H,Marcuard SP

    更新日期：2001-10-01 00:00:00

  • Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression.

    abstract：:To commemorate Edkins' discovery of gastrin in 1905, we review a century of progress in the physiology and pathobiology of gastrin and acid secretion especially as it pertains to clinical aspects of gastro-oesophageal reflux disease. Although initially ignored, Edkins' observations eventually led to the enthusiastic i...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.02817.x

    authors： Malfertheiner P,Fass R,Quigley EM,Modlin IM,Malagelada JR,Moss SF,Holtmann G,Goh KL,Katelaris P,Stanghellini V,Talley NJ,Tytgat GN,Wright NA

    更新日期：2006-03-15 00:00:00

  • Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

    abstract：BACKGROUND:Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative. AIM:To compare the clin...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15179

    authors： Drobne D,Kurent T,Golob S,Švegl P,Rajar P,Hanžel J,Koželj M,Novak G,Smrekar N,Ferkolj I,Štabuc B

    更新日期：2019-04-01 00:00:00

  • A controlled trial of ondansetron in the pruritus of cholestasis.

    abstract：BACKGROUND:In patients with pruritus of cholestasis, response to conventional drug treatment may be unsatisfactory. Activation of 5-hydroxytryptamine receptors on dermal sensory nerve-endings plays a role in the perception of pruritus. The 5-hydroxytryptamine(3) receptor antagonist, ondansetron, has been used in the tr...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2005.02430.x

    authors： O'Donohue JW,Pereira SP,Ashdown AC,Haigh CG,Wilkinson JR,Williams R

    更新日期：2005-04-15 00:00:00

  • Review article: coeliac disease in later life must not be missed.

    abstract：BACKGROUND:The presenting symptoms of coeliac disease are often subtle and the diagnosis is frequently delayed or overlooked. Therefore, especially elderly patients may be denied the benefits conferred by gluten free diet which can be dramatically life-changing. AIM:To review the occurrence, clinical features, diagnos...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.14490

    authors： Collin P,Vilppula A,Luostarinen L,Holmes GKT,Kaukinen K

    更新日期：2018-03-01 00:00:00

  • Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors.

    abstract：BACKGROUND:Several measures have been used to assess the health-related quality of life (HRQoL) of patients with eosinophilic oesophagitis (EoE). AIMS:To systematically review these HRQoL measures, to appraise measurement properties of specific instruments and to evaluate determinant factors influencing HRQoL in paedi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.14194

    authors： Lucendo AJ,Arias-González L,Molina-Infante J,Arias Á

    更新日期：2017-08-01 00:00:00

  • Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.

    abstract：BACKGROUND:Up to 80% of patients with Crohn's disease require an abdominal operation in their lifetime. As the use of vedolizumab is increasing for the treatment of Crohn's disease, it is important to understand its potential association with post-operative complications. AIM:We sought to compare 30-day postoperative ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14459

    authors： Lightner AL,McKenna NP,Tse CS,Raffals LE,Loftus EV Jr,Mathis KL

    更新日期：2018-03-01 00:00:00

  • Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease.

    abstract：BACKGROUND:The threshold plasma paracetamol concentration at which N-acetylcysteine (NAC) treatment is recommended to treat paracetamol poisoning in a patient with induced liver enzymes (for example, with chronic liver disease or taking anticonvulsant drugs) is 50% lower than in a patient without induced liver enzymes....

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.1997.00209.x

    authors： Jones AL,Jarvie DR,Simpson D,Hayes PC,Prescott LF

    更新日期：1997-08-01 00:00:00